Compare · ADCT vs LLY
ADCT vs LLY
Side-by-side comparison of ADC Therapeutics SA (ADCT) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADCT and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 8746.5x ADCT ($132.8M).
- LLY has been more active in the news (16 items in the past 4 weeks vs 6 for ADCT).
- LLY has more recent analyst coverage (25 ratings vs 19 for ADCT).
- Company
- ADC Therapeutics SA
- Eli Lilly and Company
- Price
- $1.03+6.42%
- $1233.40-1.12%
- Market cap
- $132.8M
- $1.16T
- 1M return
- -8.85%
- -
- 1Y return
- -67.51%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 16
- Recent ratings
- 19
- 25
ADC Therapeutics SA
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ADCT
- SEC Form SCHEDULE 13G filed by ADC Therapeutics SA
- SEC Form S-8 filed by ADC Therapeutics SA
- SEC Form 10-Q filed by ADC Therapeutics SA
- ADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
- ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
- Chief Medical Officer Zaki Mohamed was granted 213,900 shares, increasing direct ownership by 31% to 896,317 units (SEC Form 4)
- Chief Legal Officer Graham Peter J was granted 221,100 shares, increasing direct ownership by 36% to 841,640 units (SEC Form 4)
- Chief Financial Officer Carmona Jose was granted 203,700 shares, increasing direct ownership by 28% to 938,076 units (SEC Form 4)
- Chief Executive Officer Mallik Ameet was granted 675,000 shares, increasing direct ownership by 47% to 2,121,769 units (SEC Form 4)
Latest LLY
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- SVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)